Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aeglea Biothera (AGLE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 238,055
  • Shares Outstanding, K 21,860
  • Annual Sales, $ 5,210 K
  • Annual Income, $ -27,240 K
  • 36-Month Beta 0.05
  • Price/Sales 44.47
  • Price/Cash Flow N/A
  • Price/Book 4.05

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.07 +19.29%
on 06/04/18
12.00 -9.83%
on 06/01/18
+0.25 (+2.37%)
since 05/18/18
3-Month
7.50 +44.27%
on 04/19/18
12.00 -9.83%
on 06/01/18
-0.08 (-0.73%)
since 03/19/18
52-Week
2.81 +285.05%
on 08/17/17
12.00 -9.83%
on 06/01/18
+7.13 (+193.22%)
since 06/19/17

Most Recent Stories

More News
Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

AGLE : 10.82 (-0.64%)
AZN : 35.94 (-0.44%)
ILMN : 285.74 (-1.08%)
VRX : 24.24 (+2.89%)
PTC Therapeutics' Spinal Muscular Atrophy Study Successful

PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.

PTCT : 33.24 (-30.58%)
AGLE : 10.82 (-0.64%)
RHHBY : 26.5300 (+0.53%)
BIIB : 292.04 (+1.01%)
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer

With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.

AGLE : 10.82 (-0.64%)
MRK : 61.03 (+0.07%)
IMGN : 10.50 (+1.65%)
RHHBY : 26.5300 (+0.53%)
Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone

Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction....

AGLE : 10.82 (-0.64%)
MYL : 38.73 (+0.39%)
ILMN : 285.74 (-1.08%)
RDY : 34.87 (-0.43%)
Flex Pharma Down on Workforce Reduction, Ends Phase II Study

Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.

AGLE : 10.82 (-0.64%)
ILMN : 285.74 (-1.08%)
ANIP : 67.20 (+0.33%)
FLKS : 1.20 (-6.25%)
Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA

Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial...

AGLE : 10.82 (-0.64%)
ILMN : 285.74 (-1.08%)
RHHBY : 26.5300 (+0.53%)
AMGN : 186.19 (+1.22%)
Sarepta Inks Manufacturing Deal for Gene Therapy Program

Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.

AGLE : 10.82 (-0.64%)
SRPT : 143.93 (+36.76%)
ANIP : 67.20 (+0.33%)
PFE : 36.22 (+0.17%)
Insiders Seeing Green With AGLE At New 52-Week High

In trading on Friday, shares of Aeglea BioTherapeutics Inc touched a new 52-week high of $12.00/share. That's a 327.05% rise, or $9.19 per share from the 52-week low of $2.81 set back on 08/17/2017.

AGLE : 10.82 (-0.64%)
5 Biotech Stocks to Boost Your Portfolio's Health This Year

Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio.

AGLE : 10.82 (-0.64%)
CELG : 79.44 (+2.20%)
LGND : 195.91 (+1.25%)
CRSP : 62.06 (-0.91%)
BMRN : 95.62 (+0.04%)
ATHX : 2.06 (-10.82%)
SNY : 39.15 (-1.11%)
Clovis' Rubraca Gets Approval in Europe for Ovarian Cancer

Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.

AGLE : 10.82 (-0.64%)
AZN : 35.94 (-0.44%)
CLVS : 45.75 (+1.15%)
TSRO : 39.99 (+1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AGLE with:

Business Summary

Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical...

See More

Key Turning Points

2nd Resistance Point 11.80
1st Resistance Point 11.31
Last Price 10.82
1st Support Level 10.34
2nd Support Level 9.86

See More

52-Week High 12.00
Last Price 10.82
Fibonacci 61.8% 8.49
Fibonacci 50% 7.40
Fibonacci 38.2% 6.32
52-Week Low 2.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar